Thyroid RFA 101: The Future is Very Bright for Treating Benign Nodules and Primary Low Risk Thyroid Cancers

Thyroid RFA 101: The Future is Very Bright for Treating Benign Nodules and Primary Low Risk Thyroid Cancers

Thyroid RFA 101: The Future is Very Bright for Treating Benign Nodules and Primary Low Risk Thyroid Cancers

Thyroid RFA 101: The Future is Very Bright for Treating Benign Nodules and Primary Low Risk Thyroid Cancers

American Thyroid Association National Meeting

October 17-22 2017

Objective

1500 of the world expert thyroidologists and over

500 of the clinical endocrinologists met in Victoria BC.

My original objective was to make a presentation on the

Use of ablation procedures to treat thyroid disease. To

highlight the new safety methods and devices developed by

Dr.Baek in my presentation. To demonstrate some of

these used in my Master’s class in Thyroid RFA and PEI.

To recruit The clinical endocrinologists who do their own biopsies to Consider learning Thyroid RFA. To inform them about AACE’s formation of a thyroid RFA task force ( I am a member) to begin to develop a Training program in certification.To inform the clinical endocrinologists about the thyroidablation.net website begun in Boston 2017 at the World Thyroid Cancer Congress for thyroid ablation.

Impression

The meeting was a success and our exhibit booth was well

designed to promote Thyroid RFA. A number of endocrinologists And others attending knew about Thyroid RFA from my website and thyroid blog. The current trend in

thyroid is to develop molecular markers to be able to

Tell if a thyroid nodule is cancer, and if that cancer has the

Potential to cause serious complications or death. Every expert in the field stated that marker testing will be able To tell which nodules and cancer are safe to ablate in plac

And not need surgery. Dr.Syd Finkelstein of Interpace and Dr.Yuri Nikiforov from U of Pittsburgh both leading marker experts told be while visiting my booth take thyroid RFA will become more and more Important to treat these low risk cancers without surgery. Also, Dr.Ian Hay from the Mayo Clinic, a pioneer in ablation methods is already ablating small primary micro-papillary Cancers with ethanol. Thyroid RFA is a better fit to treat As shown by Dr.Baek. Thyroid ablation is the third arm tom surgery and active surveillance for low risk cancers.

Conclusion

We were the only exhibit booth about thyroid RFA. We had

one of several Papers on thyroidRFA. Medtronic was there

but had nothing on microwave. We recruited 6 clinical

endocrinologists for my Thyroid RFA private master’s class to learn Thyroid RFA. They do 300-500

FNAs a year and can be part of the clinical trials on the

thyroid nodules to start after training and FDA approval.

The exciting finding was the potential of microRNA to

Tell which nodules can be ablated even if they are cancers

That are low risk.Also the present use of Active Surveillance

Vs surgery of low risk primary cancers has a new option of

Thyroid RFA Ablation and ethanol ablation ( Ian Hay at

Mayo Clinic).

The objectives set forward when I proposed a booth and

paper at this meeting was met and exceeded. We now know

ThyroidRFA will be the dominate method to treat benign and

low risk cancers in the next 5 years, and replace surgery

for my happy thyroid patients.

 

 

Richard Guttler MD,FACE,ECNU

thyroid.com

 

Add Your Comment

Contact Info
1328 16th Street, Santa Monica, CA 90404
Monday – Friday
9:00 AM to 5:00 PM
(310) 393-8860